Ivacaftor pharmacokinetics and lymphatic transport after enteral administration in rats

Front Pharmacol. 2024 Feb 20:15:1331637. doi: 10.3389/fphar.2024.1331637. eCollection 2024.

Abstract

Background: Ivacaftor is a modern drug used in the treatment of cystic fibrosis. It is highly lipophilic and exhibits a strong positive food effect. These characteristics can be potentially connected to a pronounced lymphatic transport after oral administration. Methods: A series of studies was conducted to describe the basic pharmacokinetic parameters of ivacaftor in jugular vein cannulated rats when dosed in two distinct formulations: an aqueous suspension and an oil solution. Additionally, an anesthetized mesenteric lymph duct cannulated rat model was studied to precisely assess the extent of lymphatic transport. Results: Mean ± SD ivacaftor oral bioavailability was 18.4 ± 3.2% and 16.2 ± 7.8%, respectively, when administered as an aqueous suspension and an oil solution. The relative contribution of the lymphatic transport to the overall bioavailability was 5.91 ± 1.61% and 4.35 ± 1.84%, respectively. Conclusion: Lymphatic transport plays only a minor role in the process of ivacaftor intestinal absorption, and other factors are, therefore, responsible for its pronounced positive food effect.

Keywords: bioavailability; intestinal absorption; ivacaftor; lymphatic transport; pharmacokintetics.

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This study was supported by MH CZ—DRO—VFN00064165 and GAUK No. 102322. The work of PR, JŠ, AN, DD, DB, and MA was supported by The Parc platform (www.theparc.eu).